MGH's Center for Space Medicine monitoring Suni Williams return, others adapting life back on earth
Mass General Hospital launched its Center for Space Medicine Research in January of 2024. Their most recent case study is astronaut and Needham native Suni Williams who returned from space after 9 months this week.
Williams and Butch Wilmore's eight-day expedition turned into 9 months after concerns over their Boeing capsule.
The two splashed down Tuesday night off the coast of Florida.
Vladimir Ivkovic is the director of research at opportunities at the Mass General Hospital Center for Space Medicine. He has been monitoring Suni and Butch's journey – alongside other astronauts who have to acclimate from space to life on Earth.
He explained, 'We are more and more interested in understanding the actual ramifications of those missions that they will have on the human body, on human performance, on psychological functioning of these individuals.'
The Boston-based unit is now performing research funded by NASA.
Ivkovic told Boston 25 Saturday that Wilmore and Williams will undergo several changes returning to life on Earth and gravity.
This week, Ivkovic said they'll experience weakness in their muscles and bones that haven't experienced pressure from gravity in months.
Their hearts will also be forced to pump harder with gravity, which could cause fatigue and take weeks to adapt to.
He explained, 'Of course, initially it is most acute in the first 48 hours. Then it becomes more stable. But, it takes a lot of effort.'
The two will undergo extensive cardiovascular and resistive exercises to gain back their physical strength, Ivkovic says.
Emotional and psychological effects can be seen in the coming weeks as well, with more exposure to crowds, family, and the outside world.
Ivkovic and his team are not working directly with Wilmore or Williams, but have been gathering data from other astronauts who've undergone the same physical change.
They believe the physical changes they undergo could shed light on certain disorders and conditions on Earth.
Ivkovic explained, 'There's a lot of similarities in fact with some extreme situations or environments we have on earth and what we're seeing in space flight.'
Boston 25 spoke with Suni Williams' family Wednesday, who said they are giving her space to adapt over the next few weeks. Once she's able, she plans to return at some point to the Boston area.
Download the FREE Boston 25 News app for breaking news alerts.
Follow Boston 25 News on Facebook and Twitter. | Watch Boston 25 News NOW
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Opinion - After the Trump-Musk dustup, NASA has much to consider
The social media-driven feud between President Donald Trump and SpaceX CEO Elon Musk may have simmered down a bit, with the rhetoric cooling and Musk even deleting some of his ill-considered posts about Trump from X and then apologizing for them. But the shockwaves generated by the tit-for-tat insults and threats still reverberate through NASA and the commercial space sector. When Trump threatened to pull all of SpaceX's government contracts and Musk responded by threatening to decommission the Dragon spacecraft, an apocalyptic scenario that would have cripped NASA loomed. Fortunately, both men have since backed off. Even so, according to the Washington Post, NASA and the Defense Department are quietly urging commercial space companies to hurry the development of hardware that can compete with what SpaceX has to offer. Encouraging competition with SpaceX is sound policy regardless of the relationship between Trump and Musk. However, that competition is months, if not years, in the future. The next flight of the Boeing Starliner, which failed so spectacularly in 2024, will be early next year at the earliest. The Blue Origin New Glenn, an answer to the SpaceX Falcon family of rockets, may launch once more this year and is a long way from achieving Falcon-level launch cadence. It is in Trump's and Musk's interests, and that of the American space effort, that both men repair their relationship and move on. One of the issues that drove Trump and Musk apart was Trump's abrupt and inexplicable withdrawal of the nomination of Jared Isaacman, a billionaire entrepreneur and private space traveler, for NASA administrator. Musk had championed Isaacman, who is well regarded in the aerospace community, and took it to heart when Trump changed his mind about his own nominee. The resulting leadership vacuum at NASA is being filled by Congress. The Senate Commerce Committee, chaired by Sen. Ted Cruz (R-Texas), has offered its own ideas for a NASA budget. The Senate Commerce document is at odds with the White House proposal in one important aspect. Whereas the Trump budget eliminates the Space Launch System after Artemis III and the Lunar Gateway, Senate Commerce would retain the massive, expensive rocket at least through Artemis V and would build the Gateway to support future Artemis missions. A NASA administrator such as Isaacman would be able to argue for the White House's approach. As for Isaacman, some people in the MAGA world, no doubt stung by the near-universal outrage sparked by his treatment at the hands of the White House, have started to trash the former nominee in the media. A recent Daily Caller story quoted unnamed White House officials accusing Isaacman of not only giving money to Democrats but of supporting diversity, equity and inclusion initiatives at his companies and in his private spaceflights. But both of these facts were known when Isaacman was nominated. According to the story, the officials said, 'Isaacman would have been a black spot on an administration otherwise filled with Republican Trump supporters or, at least, individuals like Robert F. Kennedy Jr. who backed the president prior to the election.' To hear these unnamed sources talk, Isaacman is no better than left-wing House members Rep. Alexandria Ocasio-Cortez (D-N.Y.), Rep. Ilhan Omar (D-Minn.) and their Squad. It should be noted that even if Isaacman wanted to impose DEI policies at NASA, he couldn't because of Trump's executive order prohibiting it across the federal government. Isaacman posted to X in his own defense: 'I am a moderate and donated to both parties for different reasons … my largest contribution was to President Trump — because I support many of his policies. I definitely did not like the direction this country was going over the last 4 years.' He went on to state, 'I have never spoken against the President. I have never voted against him.' It sounds like Isaacman is very loyal to Trump, remarkable under the circumstances. The suggestion of disloyalty is spurious and against the White House's interests. Isaacman's situation could provide the basis of a rapprochement between Trump and Musk. Musk has already apologized to the president for some of his posts on X, particularly the one suggesting that Trump is named in the Department of Justice's files on Jeffrey Epstein. But the president should admit fault as well. He was deceived by some of his staff about Isaacman's character. If it is not too late, he should reverse himself a second time and send his fellow billionaire's name back into nomination. NASA, the U.S., and the Trump-Musk partnership would gain as a result. Mark R. Whittington, who writes frequently about space policy, has published a political study of space exploration entitled 'Why is It So Hard to Go Back to the Moon?' as well as 'The Moon, Mars and Beyond,' and, most recently, 'Why is America Going Back to the Moon?' He blogs at Curmudgeons Corner. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Business Wire
3 hours ago
- Business Wire
HekaBio, Japan-based Biopharma and MedTech Platform, Enters Strategic Partnership with Alfresa Holdings Corporation
TOKYO--(BUSINESS WIRE)--HekaBio K.K. (Headquarters: Chuo-ku, Tokyo; President & CEO: Robert E. Claar; hereinafter 'HekaBio') today announced the signing of a strategic partnership agreement with Alfresa Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; Representative Director & President: Ryuji Arakawa; hereinafter 'Alfresa Holdings'), the leading pharmaceutical wholesaler group in Japan. As part of this agreement, Alfresa Holdings has also made a capital investment in HekaBio. The partnership aims to accelerate the commercialization of innovative medical products in Japan. HekaBio, Japan-based Biopharma and MedTech Platform, Enters Strategic Partnership with Alfresa Holdings Corporation -- Accelerating Access to Innovative Therapies in Japan through Alfresa Group's 'Total Supply Chain Service'-- Share Background and Purpose In recent years, Japan has implemented policy reforms to address the growing access gap, where innovative therapies approved overseas are slow to come to the Japanese market. In response to these developments, HekaBio has focused on introducing cutting-edge pharmaceuticals, medical devices, and regenerative medicine products from global markets into Japan and the Asia-Pacific markets. Leveraging a proprietary global network and partnership model, HekaBio evaluates over 200 assets annually across oncology, cardiology and CNS, and supports end-to-end commercialization from licensing to clinical and regulatory development, manufacturing and sales. This partnership with Alfresa Group will enable HekaBio to advance and expand its portfolio and impact, particularly in CNS and regenerative medicine where Alfresa Group has strengths in manufacturing and in sales, including various other aspects of sales-related operations across the supply chain. Outlook Through this partnership, HekaBio and Alfresa Group aim to accelerate the introduction of high-impact, potential blockbuster therapies into the Japanese market, expanding treatment options for patients. The companies also plan to explore commercialization strategies across the Asia-Pacific region and beyond. About HekaBio HekaBio is a Japan-based, asset-light healthcare platform that accelerates patient access to global medicines and MedTech across Asia-Pacific. HekaBio reviews over 200 assets annually to in-license a select few, focusing on early-stage, de-risked opportunities in CNS, oncology, and healthy longevity. HekaBio synchronizes U.S. and Japan development timelines and leverages strategic partnerships to optimize commercial success. Japan, the world's third-largest healthcare market, serves as its launchpad for regional expansion. To learn more about HekaBio's mission and portfolio, visit About Alfresa Holdings Alfresa Holdings is the holding company for the Alfresa Group, which operates businesses ranging from the development, manufacture, and distribution of pharmaceuticals to the operation of dispensing pharmacies and is the top corporate group in Japan in terms of ethical pharmaceuticals wholesaling, with consolidated net sales exceeding ¥2.9 trillion in the fiscal year ended March 31, 2025. Guided by its corporate philosophy, 'we create and deliver a fresh life for all,' the entire Group supports supply chains for pharmaceuticals and other products, a form of social infrastructure underpinning Japanese healthcare, contributing to a wide range of medical needs. For more information:
Business Insider
8 hours ago
- Business Insider
I bring healthcare to people's homes in Singapore. AI is changing home care, but it can't replace clinicians.
This as-told-to essay is based on a conversation with Dr. Shravan Verma, the cofounder and CEO of Speedoc, a Singapore-based health tech startup. This interview has been edited for length and clarity. As someone who has worked in both tertiary hospitals as well as some underserved environments, I saw the opportunity to create a virtual hospital that brings healthcare directly to where patients are, starting with their homes. Why should access to hospital-grade care be dependent on geography or infrastructure? The home will become the new center of care, and AI will be the invisible infrastructure enabling this shift. With AI software becoming more sophisticated and AI-enabled hardware becoming more accessible, care will become more personalized. I see the future of home care as a hybrid, with AI-enabled self-care tools integrated into regulated, human-involved systems. Singapore and the region are more ready than we think. In Singapore, we're already seeing strong policy alignment and public trust in digital systems. Even the patient mindset is maturing around receiving care outside traditional hospitals. Embedded AI AI is already a foundational layer of our operations. Our command center uses AI to triage patient cases, optimize our logistics for clinician dispatch, and even anticipate escalation risks. For example, AI models continuously analyze data from devices like pulse oximeters, BP monitors, or even passive sensors. If a patient's vitals begin trending dangerously, clinicians are alerted before deterioration sets in. We've prevented emergency room visits this way. The next phase is using AI for predictive care, orchestration, preempting deterioration in chronic patients, automating routine follow-ups, and eventually building an AI copilot for our clinicians. Clinicians expect systems to support and not slow down their work. Our nurses and doctors are asking for tools that reduce admin burden, triage smarter, and give them more actionable insights. Patients, too, are increasingly comfortable with these digital touchpoints, but they do want these to feel personalized and intelligent. Clinicians will be transformed, not replaced, by AI AI will transform but not replace the clinician role, especially in home settings. Their role becomes more relational as AI simplifies documentation and supports better decision-making. AI can't replicate the presence, empathy, and nuanced judgment in uncertain or complex conditions. It can't speak with family and understand what's best for the patient. AI can tell you — worst case — you're having a heart attack, but then what do you do about it? I know the diagnosis of a heart attack, but I need to be sent immediately to a hospital, make sure that I get stented, and get the catheterization, which is still very human-driven. Somebody also has to ensure continuity, ensure the administration of treatments and follow-ups, and ensure that the patients are improving as they're supposed to. Many of the conditions we treat at home also require IV drips, IV antibiotics, blood tests, and urine tests. Lead with outcomes, not AI Chatbots and AI tools can handle the first mile of care, but they must escalate to qualified professionals when needed. We need to be vigilant about bias in training data and sometimes a lack of contextual nuances in understanding what a patient's condition is. One of the key challenges with AI is confabulation, which is AI coming up with analysis or data that didn't exist for the patient. Governance, transparency, and auditability must be baked into every AI deployment. When it comes to AI-driven home care, the key is not to lead with AI but with outcomes and convenience. Patients don't really ask, "Is this AI?" They ask, "Is this faster, safer, more personalized?" When AI helps a patient get triaged within minutes or enables a nurse to show up at the right time with the right medication, that builds confidence. The real unlock is making sure AI remains transparent, empathetic, and always augments, not replaces, the human touch.
